NCT04580290

Brief Summary

The objective of the study is to assess re-rupture rates and patient outcomes from subjects with at least 5 year follow up, treated with the JewelACL device for ACL reconstruction. The impact of fixation type and autograft augmentation will also be assessed. All adverse events related to the JewelACL device will be recorded. This study is Sponsored by Xiros.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 2, 2020

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

October 5, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 8, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 9, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 9, 2021

Completed
7 months until next milestone

Results Posted

Study results publicly available

November 2, 2021

Completed
Last Updated

November 2, 2021

Status Verified

October 1, 2021

Enrollment Period

6 months

First QC Date

October 5, 2020

Results QC Date

August 31, 2021

Last Update Submit

October 4, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Occurrence of Re-ruptures

    Number of participants with re-rupture that were implanted with the jewelACL device for ACL reconstruction

    Five Year

Study Arms (2)

JewelACL + Autograft (Hybrid)

JewelACL + Autograft (Hybrid)

Device: JewelACL

JewelACL only

JewelACL only

Device: JewelACL

Interventions

JewelACLDEVICE

The JewelACL is a polyester scaffold for anterior cruciate ligament (ACL) reconstruction

JewelACL + Autograft (Hybrid)JewelACL only

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Consecutive patients who have had the JewelACL device used to reconstruct the ACL, between the period of 01 October 2010 to 31 December 2014.

You may qualify if:

  • Age more than 18 years
  • Patients previously implanted with the JewelACL for Anterior Cruciate Ligament (ACL) reconstruction (Primary JewelACL cases only, no revision cases)

You may not qualify if:

  • Age less than 18 years
  • Any implantations for non-indicated conditions, as stated in the Instructions For Use Instructions for use (IFU)
  • Revision cases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Med-Polonia

Poznan, Poland

Location

MeSH Terms

Conditions

Anterior Cruciate Ligament Injuries

Condition Hierarchy (Ancestors)

Knee InjuriesLeg InjuriesWounds and Injuries

Limitations and Caveats

Reruptures can be sustained during sports trauma and cannot necessarily be attributed to device insufficiency.

Results Point of Contact

Title
Tracey Oxley
Organization
Xiros Ltd

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 5, 2020

First Posted

October 8, 2020

Study Start

October 2, 2020

Primary Completion

April 9, 2021

Study Completion

April 9, 2021

Last Updated

November 2, 2021

Results First Posted

November 2, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will not share

Locations